FcR Therapeutics

FcR Therapeutics is a private, preclinical-stage biotech focused on autoimmune diseases through a novel approach of targeting Fc receptors. The company leverages a proprietary antibody (likely nanobody) platform to develop therapeutics that modulate the dysfunctional interaction between autoantibodies and FcRs, which is a key driver of tissue damage. A significant early validation point is a strategic collaboration announced in 2025 with Grifols, a global leader in plasma medicines, to pioneer recombinant nanobody therapies. The experienced leadership team combines expertise in antibody development and entrepreneurship.

Proprietary antibody/nanobody engineering platform targeting Fc receptors (FcRs) to modulate pathological immune responses in autoimmune diseases.

The autoimmune therapeutics market is highly competitive, dominated by large molecules targeting cytokines (e.g., TNF, IL-6, IL-17) and newer modalities targeting B cells or signaling kinases. Direct Fc receptor targeting is a niche but emerging approach, with competitors potentially exploring Fc-gamma receptor modulators or FcRn inhibitors (for different mechanisms). FcR Therapeutics' focus on nanobodies for FcR modulation represents a differentiated technological angle.